AstraZeneca’s coronavirus vaccine becomes third to begin Phase three trials in the United States

British drugmaker AstraZeneca said Monday it has started Phase 3 trials of its experimental coronavirus vaccine in the United States, becoming the third company to start late-stage trials of a vaccine to prevent Covid-19.

The vaccine, developed in partnership with Oxford University, has the backing of the US federal government. Rivals Moderna and Pfizer/BioNTec already have Phase 3 trials under way, also with federal government funding.

AstraZeneca said it is “recruiting up to 30,000 adults aged 18 years or over from diverse racial, ethnic and geographic groups who are healthy or have stable underlying medical conditions, including those living with HIV, and who are at increased risk of infection from the SARS-CoV-2 virus.”

Related article One shot of coronavirus vaccine likely won't be enough?

Participants will receive two active or placebo doses, spaced four weeks apart. Currently, Phase 3 trials of AstraZeneca’s vaccine are going on in Britain, Brazil and South Africa. Trials are also planned for Japan and Russia.

The US trial is funded by the federal government’s Biomedical Advanced Development Authority and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

“NIH is committed to supporting several Phase 3 vaccine trials to increase the odds that one or more will be effective in preventing COVID-19 and put us on the road to recovery from this devastating pandemic,” said NIH director Dr. Francis Collins said in a statement. “We also know that preventing this disease could require multiple vaccines and we’re investing in those that we believe have the greatest potential for success.”

AstraZenca says it intends to enroll more than 50,000 volunteers globally, including 30,000 in the United States, as well as participants in Latin America, Asia, Europe and Africa.

A blood sample is prepared for analysis by a laboratory technician at a clinical trial sponsored by Moderna at Accel Research. (Photo by Paul Hennessy/NurPhoto via Getty Images)

Related article Moderna increases minority numbers in its vaccine trial, but still not meeting Fauci's goal

The vaccine, called by its experimental name AZD1222, combines a weakened version of a common cold virus that infects chimpanzees and a protein from the virus that causes Covid-19 to induce an immune response. The vaccine was created by Oxford University before being licensed to AstraZeneca for further development.

AstraZeneca said it will work with governments and other organizations to produce billions of doses and create broad and equitable access to the vaccine, once it’s authorized.

“Recent supply announcements with Russia, South Korea, Japan, China, Latin America and Brazil take the global supply capacity towards three billion doses of the vaccine,” AstraZeneca said in a statement.

The World Health Organization cautioned countries Monday against rushing to develop coronavirus vaccines and advised taking great care in granting emergency use authorization – a quicker route to getting a vaccine in wide use than full approval, which can take many months.

Thomas Hansler, 54, receives a COVID-19 vaccination from Yaquelin De La Cruz at the Research Centers of America in Hollywood, Florida on August 13, 2020. (Photo by CHANDAN KHANNA / AFP) (Photo by CHANDAN KHANNA/AFP via Getty Images)

Related article FDA leader says agency could consider authorization for Covid-19 vaccine before Phase 3 trials are complete, Financial Times reports

Both China and Russia say they will start deploying vaccines before completing late-stage clinical trials, and US Food and Drug Administration Commissioner Dr. r. Stephen Hahn has said if the US gets enough data from advanced stage trials, it might be possible to authorize a vaccine before the trials are completed.

AstraZeneca released a statement emphasizing its commitment to science and safety.

The company also said the vaccine will meet the strict requirements set by by global regulators.

Both Moderna and Pfizer/BioNTech are still in the process of enrolling their stated goals of 30,000 volunteers each.

Lauren Mascarenhas contributed to this story.